Cargando…
Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035001/ https://www.ncbi.nlm.nih.gov/pubmed/33868407 http://dx.doi.org/10.1155/2021/6663755 |
_version_ | 1783676637223583744 |
---|---|
author | Sedlacek, Carissa M. Leone, Michael Foster, Adam D. Hinkelman, Amy |
author_facet | Sedlacek, Carissa M. Leone, Michael Foster, Adam D. Hinkelman, Amy |
author_sort | Sedlacek, Carissa M. |
collection | PubMed |
description | Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy, immunomodulatory drugs, and analgesics, there is nothing specific for the treatment of NA. Full functional recovery can take months to years, but recurrence and/or persistence of symptoms and disability are frequent. This case reports a 22-year-old male who recovered from NA within 3 months following treatment with 1000 mg of methylprednisolone and off-label use of 0.5 g/kg of intravenous immunoglobulins (IVIG) for four consecutive days. Three years later, the patient experienced soreness and paresthesia of the shoulder following a military shooting exercise, and 0.75 g/kg of IVIG and 1000 mg of MP were prescribed for 2 consecutive days resulting in complete recovery and no recurrences to date. EMG findings, 3.5-year postinitial treatment, revealed improvement in the brachial plexopathy. This provides support for the combined use of IVIG and glucocorticoids in the treatment of NA and highlights the need for further studies investigating whether this combined treatment regimen may accelerate recovery and improve long-term outcomes for patients diagnosed with NA. |
format | Online Article Text |
id | pubmed-8035001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-80350012021-04-16 Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine Sedlacek, Carissa M. Leone, Michael Foster, Adam D. Hinkelman, Amy Case Rep Med Case Report Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy, immunomodulatory drugs, and analgesics, there is nothing specific for the treatment of NA. Full functional recovery can take months to years, but recurrence and/or persistence of symptoms and disability are frequent. This case reports a 22-year-old male who recovered from NA within 3 months following treatment with 1000 mg of methylprednisolone and off-label use of 0.5 g/kg of intravenous immunoglobulins (IVIG) for four consecutive days. Three years later, the patient experienced soreness and paresthesia of the shoulder following a military shooting exercise, and 0.75 g/kg of IVIG and 1000 mg of MP were prescribed for 2 consecutive days resulting in complete recovery and no recurrences to date. EMG findings, 3.5-year postinitial treatment, revealed improvement in the brachial plexopathy. This provides support for the combined use of IVIG and glucocorticoids in the treatment of NA and highlights the need for further studies investigating whether this combined treatment regimen may accelerate recovery and improve long-term outcomes for patients diagnosed with NA. Hindawi 2021-04-01 /pmc/articles/PMC8035001/ /pubmed/33868407 http://dx.doi.org/10.1155/2021/6663755 Text en Copyright © 2021 Carissa M. Sedlacek et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Sedlacek, Carissa M. Leone, Michael Foster, Adam D. Hinkelman, Amy Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title | Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title_full | Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title_fullStr | Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title_full_unstemmed | Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title_short | Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine |
title_sort | off-label use of intravenous immunoglobulin with methylprednisolone to treat parsonage–turner syndrome in a united states marine |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035001/ https://www.ncbi.nlm.nih.gov/pubmed/33868407 http://dx.doi.org/10.1155/2021/6663755 |
work_keys_str_mv | AT sedlacekcarissam offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine AT leonemichael offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine AT fosteradamd offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine AT hinkelmanamy offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine |